Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 0.92%.

  • Akebia Therapeutics' EBITDA Margin rose 544600.0% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.07%, marking a year-over-year decrease of 3190000.0%. This contributed to the annual value of 43.33% for FY2024, which is 4759200.0% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' EBITDA Margin is 0.92%, which was up 544600.0% from 0.4% recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' EBITDA Margin peaked at 23.3% during Q2 2022, and registered a low of 156.94% during Q2 2021.
  • For the 5-year period, Akebia Therapeutics' EBITDA Margin averaged around 56.44%, with its median value being 49.04% (2024).
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' EBITDA Margin was 2775000bps (2021), while the steepest drop was -643800bps (2021).
  • Over the past 5 years, Akebia Therapeutics' EBITDA Margin (Quarter) stood at 121.13% in 2021, then skyrocketed by 91bps to 10.88% in 2022, then surged by 96bps to 0.48% in 2023, then crashed by -10158bps to 49.04% in 2024, then surged by 102bps to 0.92% in 2025.
  • Its EBITDA Margin stands at 0.92% for Q3 2025, versus 0.4% for Q2 2025 and 10.66% for Q1 2025.